Invivyd
IVVD0.58167.11% ( +0.0386 )
Invivyd (IVVD)
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and tr...
- Open
- 0.5568
- High
- 0.5902
- Low
- 0.5508
- Prev. Close
- 0.5430
- Volume
- 3.05M
- Turnover
- 1.74M
- Avg Price
- 0.5696
- Bid/Ask Ratio
- --
- Amplitude
- 7.26%
- 52wk High
- 3.0700
- Volume Ratio
- 0.72
- Turnover Ratio
- 1.42%
Invivyd Analyst Rating
View MoreForecast & Rating
Jul 8, 2026Price forecast
$10.001619.39%
Forecast & RatingStrong buy
3analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 24 at 03:05 PM
Invivyd gets Nasdaq notice after shares trade below $1 minimum bid price
- Global Report · Jul 21 at 04:12 AM
The Physical Layer of the 2026 Economy is Undergoing a Quiet Rebuild
- Price Alert · Jul 8 at 01:37 PM
U.S. stock market midday update: FDA terminates PEMGARDA authorization, Invivyd drops 9.13%
- MorningStar · Jul 6 at 04:07 PM
Healthcare Stocks Decline as Investors Rotate Away from Safety — Healthcare Roundup
- StockTitan · Jul 5 at 10:01 PM
Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA | IVVD Stock News
- PUBT · Jul 2 at 06:01 AM
Invivyd grants 493,000 stock options to 14 new hires at $0.85 per share
